Single dose study of febuxostat (80 mg) in healthy subjects.
Phase 1
Recruiting
- Conditions
- Chronic goutMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12617001346369
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Healthy subjects
Exclusion Criteria
Subject with a history of any chronic disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of febuxostat in uric acid regulation for chronic gout management?
How does febuxostat compare to allopurinol in reducing serum urate levels and gout flare frequency?
What biomarkers are associated with febuxostat efficacy in hyperuricemia and musculoskeletal comorbidities?
What are the known adverse events of febuxostat in phase I trials and how are they managed?
Are there combination therapies involving febuxostat and IL-1 inhibitors for refractory gout treatment?